• Re-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA1
  • Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net revenue and adjusted EBITDA1 
  • Continued strong performance in Germany and Poland, contributing to profitable international growth expectations and leadership positions in the two largest EU markets, including #1 market share by revenue in Poland
  • UK market expansion underway, with recently announced acquisition of Internode Pharma and HAP Pharma Limited expected to support further market share growth

EDMONTON, AB, Sept. 16, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (NASDAQ:ACB), the leading Canadian-based global medical cannabis company, today provided a business update, highlighting the expected additional benefits of the Safari Flower Company acquisition, continued strong performance in key high margin international markets, and reaffirmed its fiscal year 2027 Q2 guidance.